logo-loader
viewInnovus Pharmaceuticals, Inc.

Innovus Pharma's memory supplement aces clinical trials

RecalMax was tested in a four-month human clinical trial on 72 patients with low memory and learning.

Parkinson's or Alzheimer's patient with nurse
Parkinson's and Alzheimer's are characterized by neurological problems affecting memory

Innovus Pharma's (OTCQB: INNV) supplement RecalMax has aced clinical trials and could prove its worth in an US$11bn neurodegenerative market.

RecalMax was tested in a four-month human clinical trial on 72 patients with low memory and learning.

After taking one capsule twice a day for 16 weeks, patients reported a 115% increase in the recall of words and names, a 49.5% increase in maintaining thoughts when distracted, and a 35% increase in processing speed.

The supplement was also well-tolerated with no serious adverse events reported.

Parkinson's disease and Alzheimer's disease are the two most prevalent medical conditions falling into the neurodegenerative market.

The market is estimated at around US$11bn annually.

Both are characterized by neurological problems affecting memory, learning, and nerve function, eventually leading to premature death.

Innovus Pharma estimates that the immediate market for RecalMax could be worth around US$3bn.

Management believes that it can capture enough of the market to generate about US$5mln in annual revenue by deploying the treatment across its well-established Beyond Human Platform and online marketing channels.

Quick facts: Innovus Pharmaceuticals, Inc.

Price: - -

OTCMKTS:INNV
Market: OTCQB
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Protech Home Medical has a full treasury as they look for rapid growth in...

Protech Home Medical (CVE: PTQ- OTCQX: PTQQF) CEO Greg Crawford joined Steve Darling from Proactive to discuss the home medical equipment industry company. That company provides devices like ventilators and oxygen concentrators. Crawford told Proactive the company just completed a large...

1 day, 4 hours ago

2 min read